Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
26.35
-0.94 (-3.44%)
At close: Dec 26, 2025, 4:00 PM EST
26.43
+0.08 (0.30%)
After-hours: Dec 26, 2025, 7:39 PM EST
Edgewise Therapeutics Employees
Edgewise Therapeutics had 110 employees as of December 31, 2024. The number of employees increased by 22 or 25.00% compared to the previous year.
Employees
110
Change (1Y)
22
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,429,464
Market Cap
2.79B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Dec 31, 2021 | 31 | 12 | 63.16% |
| Dec 31, 2020 | 19 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EWTX News
- 3 days ago - Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PRNewsWire
- 23 days ago - Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 5 weeks ago - Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors - PRNewsWire
- 6 weeks ago - Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers - PRNewsWire
- 7 weeks ago - Edgewise Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 3 months ago - Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society - PRNewsWire